Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
82 studies found for:    "Rubella"
Show Display Options
RSS Create an RSS feed from your search for:
"Rubella"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Rubella Susceptibility in Multiparous Women
Conditions: Rubella;   Vaccine
Intervention:
2 Completed Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination
Condition: Measles/Rubella
Intervention: Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
3 Completed Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination
Condition: Measles/Rubella
Intervention: Drug: Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
4 Completed Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
Conditions: Rubella;   Measles
Intervention: Biological: Double viral (MR) vaccine
5 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
Condition: Measles; Mumps; Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
6 Completed Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
7 Completed Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
8 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Conditions: Rubella;   Mumps;   Measles
Interventions: Biological: Priorix®;   Biological: M-M-R®II;   Biological: Kinrix®;   Biological: Varivax®
9 Completed Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Conditions: Measles;   Mumps;   Rubella
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762);   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
10 Completed Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
Conditions: Mumps;   Rubella;   Measles
Intervention: Biological: MMR (Mumps, Measles and Rubella)
11 Completed Coadministration of Measles-rubella and Rotavirus Vaccines
Conditions: Measles Antibody Seroconversion;   Rubella Antibody Seroconversion;   Rotavirus GMT;   Rotavirus IgA Seropositivity
Interventions: Biological: Rotarix vaccine;   Biological: measles-rubella vaccine
12 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Measles;   Rubella;   Mumps;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
13 Completed Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Rubella;   Measles;   Varicella
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
14 Completed Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Conditions: Mumps;   Varicella;   Rubella;   Measles
Intervention: Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)
15 Completed Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Conditions: Measles;   Mumps;   Rubella;   Varicella
Interventions: Biological: MMR Bio-Manguinhos;   Biological: MMR GlaxoSmithKline
16 Active, not recruiting Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies
Condition: Pregnancy
Intervention: Biological: Determination of Anti-Rubella Antibody, E1
17 Completed Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine);   Biological: GSK Biologicals' 208136, new formulation
18 Completed
Has Results
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
Conditions: Japanese Encephalitis;   Measles;   Mumps;   Rubella
Intervention: Biological: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
19 Completed Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136
Conditions: Measles;   Varicella;   Mumps;   Rubella
Interventions: Biological: PriorixTM;   Biological: VarilrixTM;   Biological: GSK Biologicals' vaccine 208136
20 Completed Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
Conditions: Rubella;   Mumps;   Measles
Intervention: Biological: MMR vaccine (Priorix)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.